Menu
The Pierrel group, quoted on the Milan stock exchange MTA market, operates in the dental sector with a high quality line of anaesthetics produced in total asepsis under the Pierrel Pharma brand, and in the broader field of services outsourcing for the dental pharmaceuticals industry. Pierrel develops and produces medicinal specialties under its own brand as well as on a Contract Manufacturing basis on its own premises, authorised for the production, control, packaging and release of medicinal products by the AIFA, EMA, and the FDA, and provides consulting services for the development of new molecules and pharmaceuticals through its associate ‘Pierrel Research international’, with branches in over 20 countries worldwide. In the dental sector, Pierrel Pharma handles the registration and commercial development of products under its own brand, and is an indispensable partner for many leading international dental anaesthetics manufacturers. Now rapidly expanding on the domestic and international market, Pierrel’s articaina manufacturered in asepsis, better known throughout the world under as ‘Orobòloc’, is currently available in the USA, Canada, Russia, the UK, France, Germany, Poland and Austria, and is pending approval in many Arabic, Balkan and Asian States.
Pierrel Pharma is also active in the development and marketing of significant new medical devices, like GOCCLES (Glasses for Oral Cancer – Curing Light Exposed – Screening), a revolutionary optical device for directly appraising pre-cancerous lesions in the oral cavity, which it developed at Rome’s Università Cattolica, and which has won numerous prestigious international awards, and like the ORABLOC DISPOSABLE INJECTOR, a disposable syringe ready-to-use with a cartridge of articaina, which is not only practical and economical, but extremely safe as well, thanks to the protection system that prevents replacement of the needle cap to prevent accidental, potentially infected puncture.
